Macrogenics Analyst Ratings
H.C. Wainwright Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $4
TD Cowen Maintains Macrogenics(MGNX.US) With Hold Rating
Stifel Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $6
Evercore Maintains Macrogenics(MGNX.US) With Buy Rating
MacroGenics (MGNX) Receives a Hold From TD Cowen
Macrogenics Analyst Ratings
H.C. Wainwright Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $4
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Medtronic (MDT)
Citi Maintains Macrogenics(MGNX.US) With Buy Rating, Cuts Target Price to $14
Macrogenics Analyst Ratings
Buy Rating Affirmed for MacroGenics: Potential Growth Amid Oncology Trials and Solid Financials
MacroGenics (MGNX) Receives a Buy From Barclays
Buy Rating Affirmed for MacroGenics Ahead of ESMO Meeting Amidst Positive Financials and Speculative Growth Scenarios
Macrogenics Analyst Ratings
BMO Capital Maintains Market Perform on Macrogenics, Lowers Price Target to $5
Maintaining Hold on MacroGenics: Discontinued Vobra Duo and Low Conviction in Competitive Market
TD Cowen Maintains Macrogenics(MGNX.US) With Hold Rating
Hold Rating on MacroGenics Amid Trial Uncertainties and Safety Concerns
Macrogenics Analyst Ratings